2012
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)
Azar Y, Shainer R, Almogi-Hazan O, Bringer R, Compton SR, Paidas MJ, Barnea ER, Or R. PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model). Transplantation And Cellular Therapy 2012, 19: 519-528. PMID: 23266739, DOI: 10.1016/j.bbmt.2012.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Marrow TransplantationCell ProliferationDendritic CellsGraft vs Host DiseaseGraft vs Leukemia EffectImmune ToleranceInflammationInterferon-gammaInterleukin-17LiverMiceMice, Inbred BALB CMice, Inbred C57BLNitric Oxide Synthase Type IIOxidative StressPeptidesSkinSpleenSurvival AnalysisT-Lymphocytes, RegulatoryTransplantation, HomologousConceptsBone marrow transplantationBeneficial GVL effectPreImplantation FactorAcute GVHDGVL effectHost diseaseImmune responseInducible nitric oxide synthase (iNOS) expressionAllogeneic bone marrow transplantationNitric oxide synthase expressionOxidative stressIL-17 levelsIFN-γ levelsSystemic immune responsesOxide synthase expressionAntigen-presenting cellsMurine BMT modelT cell proliferationNitric oxide secretionDonor-recipient matchingChemokine gene expressionLipopolysaccharide-activated macrophagesAcute graftAllogeneic embryosBeneficial graft
2002
Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T, Liu C, Lowler K, Dranoff G, Ferrara J. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Research 2002, 62: 796-800. PMID: 11830535.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationBone marrow transplantationDonor leukocyte infusionImmunization of donorsLeukocyte infusionMarrow transplantationTumor vaccinesT cellsT cell-depleted allogeneic bone marrow transplantationTumor-specific T-cell responsesTumor vaccine efficacyDonor T cellsRecurrence of malignancyPotent antitumor immunityT cell responsesAnalysis of splenocytesT cell proliferationGranulocyte-macrophage colony-stimulating factorPotent T-cell proliferationNovel treatment strategiesColony-stimulating factorSpecific antitumor activityB16 melanoma cellsBeneficial graftHarmful graft
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply